Low LeverageThe company’s very low debt profile provides a durable solvency buffer that reduces near-term default risk and interest burden. This conservative capital structure gives management time to execute R&D or commercialization plans without immediate debt-driven liquidity pressure, supporting long-term optionality.

Large Equity Base / Funding AccessSubstantial increases in equity indicate proven capital access and a larger balance sheet to underwrite operations and development. Durable access to funding supports continued R&D and clinical/commercial activities, extending runway and allowing strategic investment even amid operating losses.

Early Revenue RecoveryRevenue increased in 2025 from a depressed 2024 level, signaling initial signs of commercialization or recurring sales returning. If sustained, this upward trend can form the basis for scaling operations, improving unit economics and enabling progress toward margin improvement over the medium term.

Bears Say

Persistent Cash BurnConsistent negative operating cash flow demonstrates structural cash consumption to run the business, forcing reliance on external financing. Over months this erodes liquidity, raises dilution or refinancing risk, and constrains ability to invest organically until operations generate sustainable positive cash flow.

Deep, Recurring LossesVery large operating and net losses reflect heavy cost intensity and lack of operating leverage. Persistently negative margins threaten equity returns and require continual capital injections; until structural cost reductions or scalable revenue are achieved, profitability remains a distant objective.

Highly Volatile RevenueExtreme year-to-year revenue swings reduce predictability of future cash flows and complicate operational planning. Such volatility suggests reliance on one-off items or intermittent sales, increasing execution risk for commercialization and making sustainable margin expansion and forecasting more difficult.

FLERIE FAQ

What was InDex Pharmaceuticals Holding AB’s price range in the past 12 months?

InDex Pharmaceuticals Holding AB lowest stock price was kr33.25 and its highest was kr47.70 in the past 12 months.

What is InDex Pharmaceuticals Holding AB’s market cap?

InDex Pharmaceuticals Holding AB’s market cap is kr2.69B.

When is InDex Pharmaceuticals Holding AB’s upcoming earnings report date?

InDex Pharmaceuticals Holding AB’s upcoming earnings report date is Apr 15, 2026 which is in 28 days.

How were InDex Pharmaceuticals Holding AB’s earnings last quarter?

InDex Pharmaceuticals Holding AB released its earnings results on Jan 21, 2026. The company reported -kr6.985 earnings per share for the quarter, missing the consensus estimate of N/A by -kr6.985.

Is InDex Pharmaceuticals Holding AB overvalued?

According to Wall Street analysts InDex Pharmaceuticals Holding AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does InDex Pharmaceuticals Holding AB pay dividends?

InDex Pharmaceuticals Holding AB does not currently pay dividends.

What is InDex Pharmaceuticals Holding AB’s EPS estimate?

InDex Pharmaceuticals Holding AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does InDex Pharmaceuticals Holding AB have?

InDex Pharmaceuticals Holding AB has 77,455,960 shares outstanding.

What happened to InDex Pharmaceuticals Holding AB’s price movement after its last earnings report?

InDex Pharmaceuticals Holding AB reported an EPS of -kr6.985 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.137%.

Which hedge fund is a major shareholder of InDex Pharmaceuticals Holding AB?

Currently, no hedge funds are holding shares in SE:FLERIE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

InDex Pharmaceuticals Holding AB

Flerie AB (publ) is a venture capital firm specializing in early-stage investments. It seeks to invest in biotech and pharma companies engaged in drug development and associated tools or applications tackling major medical challenges of our time. The firm seeks to invest in Europe, United States and Israel. Flerie AB (publ) was founded in 2011 and is based in Stockholm, Sweden with additional office in London, United Kingdom.